Recent advances in antibody-drug conjugates for the treatment of gastric cancer

Abstract

Antibody-drug conjugates (ADCs), generally consisting of cytotoxic agents conjugated to monoclonal antibodies via linkers, are a new class of targeted antitumor therapeutics that combine the advantages of high specificity of antibody and high cytotoxicity of chemotherapy drugs. After decades of preclinical and clinical research, a group of ADCs have been widely used for treatments of many types of tumors. This review summarizes recent advances in ADCs for the treatment of gastric cancer.

Keywords

• antibody-drug conjugates
• gastric cancer
• recent advances